RaQualia Pharma Inc. AI Stock Analysis
Want to see JP:4579 full AI Analyst Report?
RaQualia Pharma Inc. (4579) AI Stock Analysis
RaQualia Pharma Inc.
(TSE/TYO:4579)
RaQualia Pharma's overall score is primarily supported by its solid financial foundation, highlighted by low leverage and a recent recovery in profitability and cash flow. While short-term technical indicators show bullish momentum, the stock faces long-term bearish trends and overbought signals. Furthermore, an elevated P/E ratio indicates significant valuation risk, capping the overall rating.
RaQualia Pharma Inc. (4579) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 16.82B
- Dividend Yield
- ―
- Average Volume (3M)
- 175.16K
- Price to Earnings (P/E)
- 72.2
- Beta (1Y)
- 1.14
- Revenue Growth
- 31.84%
- EPS Growth
- ―
- Country
- Japan
- Employees
- 85
- Sector
- General
- Sector Strength
- 55
- Industry
- Biotechnology
RaQualia Pharma Inc. Business Overview & Revenue Model
Company Description
RaQualia Pharma Inc., established in 2008 and based in Nagoya, Japan, is a pharmaceutical company dedicated to the global research and development of innovative drug compounds. Its human therapeutic pipeline features several key candidates. Tegopraza...
RaQualia Pharma Inc. Financial Statement Overview
Summary
Financial health is stabilized by a strong balance sheet, featuring a low debt-to-equity ratio of 0.34 and high gross profit margins of 79.5%. Recent trailing-twelve-month data highlights a return to profitability and robust free cash flow generation. However, historical volatility in revenue and a low return on equity (2.2%) remain limiting factors.
Income Statement
72PositiveBalance Sheet
84Very PositiveCash Flow
68Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.90B | 3.98B | 3.11B | 1.90B | 2.92B | 2.78B |
| Gross Profit | 3.10B | 3.27B | 2.48B | 1.66B | 2.69B | 2.46B |
| EBITDA | 846.90M | 985.17M | 188.27M | -111.80M | 1.00B | 1.02B |
| Net Income | 161.22M | 273.12M | -495.03M | -323.66M | 723.39M | 755.79M |
Balance Sheet | ||||||
| Total Assets | 11.01B | 10.51B | 9.66B | 6.93B | 6.26B | 5.23B |
| Cash, Cash Equivalents and Short-Term Investments | 4.70B | 3.24B | 3.34B | 3.76B | 3.93B | 2.66B |
| Total Debt | 2.69B | 2.90B | 3.45B | 432.02M | 222.34M | 39.07M |
| Total Liabilities | 3.18B | 3.62B | 4.08B | 809.83M | 760.67M | 446.19M |
| Stockholders Equity | 7.83B | 6.90B | 5.57B | 6.12B | 5.50B | 4.79B |
Cash Flow | ||||||
| Free Cash Flow | 458.80M | -423.98M | 84.24M | -940.80M | 1.45B | 260.61M |
| Operating Cash Flow | 499.45M | -356.63M | 180.94M | -718.60M | 1.48B | 366.03M |
| Investing Cash Flow | -115.43M | 124.32M | -3.67B | -135.37M | -47.65M | -279.25M |
| Financing Cash Flow | 807.34M | 380.26M | 2.98B | 793.45M | -29.56M | -16.44M |
RaQualia Pharma Inc. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4579, the sentiment is Positive. The current price of 646.00 is above the 20-day moving average (MA) of 630.10, above the 50-day MA of 602.92, and below the 200-day MA of 681.20, indicating a neutral trend. The MACD of 13.84 indicates Negative momentum. The RSI at 54.06 is Neutral, neither overbought nor oversold. The STOCH value of 84.90 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4579.
RaQualia Pharma Inc. Peers Comparison
Overall Rating
JP:456571Outperform- JP:457965Neutral
JP:458851Neutral
JP:458748Neutral
JP:456342Neutral
JP:457141Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| JP:4565 | 71Outperform | JPY 165.60B | -30.31 | -8.51% | ― | 23.72% | 12.48% |
| JP:4579 | 65Neutral | JPY 17.36B | 72.18 | ― | ― | 31.84% | ― |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| JP:4588 | 51Neutral | JPY 226.57B | -152.49 | ― | ― | 1748.97% | 35.11% |
| JP:4587 | 48Neutral | JPY 140.34B | -47.42 | -5.85% | ― | 14.25% | 50.07% |
| JP:4563 | 42Neutral | JPY 10.72B | -2.83 | -163.39% | ― | 19.67% | 84.06% |
| JP:4571 | 41Neutral | JPY 6.37B | -4.98 | -33.61% | ― | 48.92% | -46.91% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:4579 | RaQualia Pharma Inc. | 646.00 | 105.00 | 19.41% | |
| JP:4563 | AnGes | 27.00 | -48.00 | -64.00% | |
| JP:4587 | Peptidream | 1065.00 | -518.50 | -32.74% | |
| JP:4565 | Sosei Group Corporation | 1813.00 | 954.00 | 111.06% | |
| JP:4571 | NanoCarrier Co., Ltd. | 67.00 | -83.00 | -55.33% | |
| JP:4588 | Oncolys BioPharma, Inc. | 8410.00 | 7342.00 | 687.45% |
RaQualia Pharma Inc. Corporate Events
RaQualia Pharma Reports Nine-Month Results Through September 2026
RaQualia Pharma Inc. reported consolidated net sales of ¥2.35 billion for the nine months ended September 30, 2026, up 1.7% from a year earlier. Operating loss narrowed to ¥238 million from ¥344 million, ordinary loss narrowed to ¥261 million from ¥4...
RaQualia Pharma Narrows Sales, Widens Loss but Strengthens Equity in First-Half 2026
RaQualia Pharma reported net sales of ¥1.46 billion for the first half of 2026, down 5.2% year-on-year, and a deeper loss attributable to owners of the parent of ¥466 million, as operating profit remained negative. Despite the weaker earnings and a b...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 17, 2026